Topics
Gliomas | Treatment | Targeted therapy | Anlotinib
Home > Publications > Topics > Gliomas > Treatment > Targeted therapy > Anlotinib
*Xu L, Yu D, Li F, Ding X, Cao Y.
A
retrospective study of 30 cases evaluating the efficacy and safety
of anlotinib plus Temozolomide for recurrent/residual glioma from
a single center.
BMC
Cancer. 2025 Oct 22;25(1):1623. doi:
10.1186/s12885-025-15123-7. PMID:
41126110. Observational study. ˍ